📊 MLTX Key Takeaways
Is MoonLake Immunotherapeutics (MLTX) a Good Investment?
MoonLake Immunotherapeutics is a pre-revenue biopharmaceutical company with severe cash burn and no clear path to profitability. The company is consuming $196M in operating cash flow annually with zero revenue, relying entirely on its $334.5M cash reserve to fund operations, which provides only ~1.7 years of runway at current burn rates. While the balance sheet shows adequate liquidity and low leverage, the absence of revenue generation and worsening loss profile (-$227.3M net loss) indicate fundamental execution failures in a capital-intensive industry.
MoonLake is a pre‑revenue biotech with substantial operating losses and deeply negative ROE/ROA, but carries a strong liquidity position (9.27x current ratio) and sizeable cash balance of $334.5M. At the current burn rate (~$196M OCF), cash provides roughly 18–20 months of runway with modest leverage (0.24x D/E). Without near‑term revenue visibility, fundamentals hinge on R&D execution and non‑dilutive funding progress, with dilution risk if timelines slip.
Why Buy MoonLake Immunotherapeutics Stock? MLTX Key Strengths
- Strong cash position of $334.5M provides near-term liquidity to fund operations
- Low financial leverage with debt-to-equity ratio of 0.24x and manageable long-term debt
- Excellent current and quick ratios (9.27x) indicating short-term solvency
- Robust liquidity and cash runway (9.27x current ratio, $334.5M cash)
- Low leverage (0.24x D/E) with minimal capex needs
- Slight YoY improvement in net loss alongside disciplined balance sheet
MLTX Stock Risks: MoonLake Immunotherapeutics Investment Risks
- Zero revenue generation despite operating as a mature public company indicates complete absence of product commercialization
- Severe cash burn rate of $196M annually in operating cash flow with only ~1.7 years of runway before depletion of cash reserves
- Negative ROE of -74.7% and ROA of -53.6% demonstrate the company is destroying shareholder value at an accelerating rate
- Operating losses of $244.8M and net losses of $227.3M indicate business model failure with no profitability timeline visible
- No revenue/gross margin visibility; ongoing pre-commercial stage
- High cash burn and large operating losses driving negative ROE/ROA
- Potential dilution/refinancing need within ~2 years absent revenue or partnerships
Key Metrics to Watch
- Operating cash flow burn rate and remaining runway based on current cash reserves
- Progress toward regulatory approvals and product launches that generate revenue
- Changes in R&D spending and cash burn efficiency improvements
- Quarterly operating cash flow (burn) and cash runway
- R&D expense trend versus clinical milestones toward first revenue
MoonLake Immunotherapeutics (MLTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.27x current ratio provides a solid financial cushion.
MLTX Profit Margin, ROE & Profitability Analysis
MLTX vs Healthcare Sector: How MoonLake Immunotherapeutics Compares
How MoonLake Immunotherapeutics compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MoonLake Immunotherapeutics Stock Overvalued? MLTX Valuation Analysis 2026
Based on fundamental analysis, MoonLake Immunotherapeutics has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MoonLake Immunotherapeutics Balance Sheet: MLTX Debt, Cash & Liquidity
MLTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: MoonLake Immunotherapeutics's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.73 indicates the company is currently unprofitable.
MLTX Revenue Growth, EPS Growth & YoY Performance
MoonLake Immunotherapeutics Dividends, Buybacks & Capital Allocation
MLTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for MoonLake Immunotherapeutics (CIK: 0001821586)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MLTX
What is the AI rating for MLTX?
MoonLake Immunotherapeutics (MLTX) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 79% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MLTX's key strengths?
Claude: Strong cash position of $334.5M provides near-term liquidity to fund operations. Low financial leverage with debt-to-equity ratio of 0.24x and manageable long-term debt. ChatGPT: Robust liquidity and cash runway (9.27x current ratio, $334.5M cash). Low leverage (0.24x D/E) with minimal capex needs.
What are the risks of investing in MLTX?
Claude: Zero revenue generation despite operating as a mature public company indicates complete absence of product commercialization. Severe cash burn rate of $196M annually in operating cash flow with only ~1.7 years of runway before depletion of cash reserves. ChatGPT: No revenue/gross margin visibility; ongoing pre-commercial stage. High cash burn and large operating losses driving negative ROE/ROA.
What is MLTX's revenue and growth?
MoonLake Immunotherapeutics reported revenue of N/A.
Does MLTX pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
Where can I find MLTX SEC filings?
Official SEC filings for MoonLake Immunotherapeutics (CIK: 0001821586) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MLTX's EPS?
MoonLake Immunotherapeutics has a diluted EPS of $-3.53.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MLTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, MoonLake Immunotherapeutics has a SELL rating with 79% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MLTX stock overvalued or undervalued?
Valuation metrics for MLTX: ROE of -74.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MLTX stock in 2026?
Our dual AI analysis gives MoonLake Immunotherapeutics a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MLTX's free cash flow?
MoonLake Immunotherapeutics's operating cash flow is $-196.0M, with capital expenditures of $35.0K.
How does MLTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -74.7% (avg: 15%), current ratio 9.27 (avg: 2).